Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPO Dosing Questions Left Unanswered; More Data, More Meetings Needed

Executive Summary

Amgen does not currently have enough data to characterize the relationship between targeted hemoglobin levels in patients receiving erythropoiesis-stimulating agents and clinical outcomes in the oncologic setting
Advertisement

Related Content

Medicare ESA Policy May Find Support In FDA Letter But J&J Sees Differently
Medicare ESA Policy May Find Support In FDA Letter But J&J Sees Differently
EPO Quality Of Life Claims Unsubstantiated, FDA Says, May Be Cut From Label
Reintroduction Of Treatment Target For ESAs For Kidney Failure?
Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach
EPO DTC Ads Create Impression Unsupported By Data, FDA And ODAC Agree
CMS May Take Studious Approach To Covering ESAs In Cancer Setting
EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
Amgen, J&J Barred From Marketing Procrit, Aranesp Chemo-Anemia Benefit
Aranesp/Procrit Trial Tumor Biopsy Collection Not Feasible, Cmte. Says
Advertisement
UsernamePublicRestriction

Register

PS048377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel